Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 9.82B +225.1% |
| Revenue (ttm) | 105.00M +134.8% |
| Net Income | -299.60M |
| EPS | -3.21 |
| Shares Out | 83.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 415,926 |
| Open | 119.40 |
| Previous Close | 120.23 |
| Day's Range | 117.48 - 121.98 |
| 52-Week Range | 39.84 - 130.05 |
| Beta | 1.95 |
| Analysts | Strong Buy |
| Price Target | 130.91 (+10.8%) |
| Earnings Date | Aug 5, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $130.91, which is an increase of 10.80% from the latest price.
News
Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Kymera Therapeutics (KYMR) to $135 from $119 and keeps an Overweight rating on the shares. The company continues to…
Kymera Therapeutics price target raised to $135 from $120 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Kymera Therapeutics (KYMR) to $135 from $120 and keeps a Buy rating on the shares. The firm updated the company’s…
Kymera Therapeutics price target raised to $139 from $133 at Barclays
Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $139 from $133 and keeps an Overweight rating on the shares.
Kymera Therapeutics Earnings Call Transcript: Q2 2026
Accelerated clinical progress with KT-621 and KT-579, strong financial position with $1.5B cash runway into 2029, and multiple value-driving milestones ahead. Leadership transitions and robust pipeline advancement position the company for late-stage growth.
Kymera Therapeutics Earnings release: Q2 2026
Kymera Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Kymera Therapeutics Quarterly report: Q2 2026
Kymera Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Kymera Therapeutics Slides: Q2 2026
Kymera Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate b...
Kymera Therapeutics Slides: Corporate presentation
Kymera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Kymera Therapeutics initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Kymera Therapeutics (KYMR) with a Hold rating and $120 price target Kymera is the leader in the field of targeted protein degradation, with a proprietary…
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics price target raised to $135 from $125 at Guggenheim
Guggenheim raised the firm’s price target on Kymera Therapeutics (KYMR) to $135 from $125 and keeps a Buy rating on the shares. Kymera could gain significant value if KT-579’s 2026…
Kymera Therapeutics CMO Jared Gollob to retire, Terence Rooney to succeed
Kymera Therapeutics (KYMR) announced the appointment of Terence Rooney as chief medical officer. Rooney is an accomplished drug development leader with extensive experience advancing immunology therap...
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his rol...
Kymera Therapeutics price target raised to $140 from $120 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Kymera Therapeutics (KYMR) to $140 from $120 and keeps an Outperform rating on the shares. The firm cites the acceleration…
Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics (KYMR) to Sector Perform from Outperform with a price target of $115, up from $106. While the firm believes STAT6 degrader ‘621…
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026...
Kymera Therapeutics price target raised to $125 from $110 at BofA
BofA raised the firm’s price target on Kymera Therapeutics (KYMR) to $125 from $110 and keeps a Buy rating on the shares. Following the announcement last week that enrollment in…
Kymera Therapeutics price target raised to $155 from $117 at B. Riley
B. Riley raised the firm’s price target on Kymera Therapeutics (KYMR) to $155 from $117 and keeps a Buy rating on the shares. The company unexpectedly announced completing BROADEN2 Phase…
Kymera Therapeutics price target raised to $136 from $116 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Kymera Therapeutics (KYMR) to $136 from $116 and keeps a Buy rating on the shares. Kymera is viewed positively following…
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Kymera Therapeutics (KYMR) to $129 from $106 and keeps a Buy rating on the shares. The firm said Kymera announced…
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
Kymera Therapeutics stock gained on Thursday after the company revealed quick enrollment in a clinical trial.
Kymera Therapeutics rises 18.6%
Kymera Therapeutics (KYMR) is up 18.6%, or $18.58 to $118.45.
Kymera Therapeutics completes enrollment in BROADEN2 trial
Kymera Therapeutics (KYMR) announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopi...
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expec...